Latest Asx Company Filings News

Scalare Partners has acquired Brisbane-based virtual CFO provider Planet Startup, enhancing its services for early-stage tech ventures and signaling continued growth through strategic acquisitions.

Metal Powder Works Limited reports its FY25 annual results, highlighting the accounting treatment of its reverse acquisition and a significant goodwill write-off tied to legacy operations.

Eastern Resources Limited has secured a farm-in agreement to earn up to 80% interest in Queensland’s Marengo Gold Project, a historically rich goldfield with promising high-grade assays and multiple exploration targets.

Nyrada Inc. has announced successful Phase I trial results for its lead drug candidate Xolatryp, confirming safety and pharmacokinetics that pave the way for a Phase IIa trial targeting heart attack patients next year.

Dynamic Metals Limited has identified a significant gold-in-soil anomaly at its Courvoisier prospect within the Widgiemooltha Project, signalling promising potential for bedrock-hosted gold mineralisation. Meanwhile, assay results from recent drilling at Chalice South are eagerly awaited.

Desert Metals has confirmed significant gold mineralisation over a 1.2km strike at its King Kong prospect in Côte d’Ivoire, underpinning plans for expanded exploration across its Adzope project.

Mustang Energy has initiated a significant 2,000-metre diamond drilling campaign at the Surprise Creek Uranium-Copper Project in Canada’s Athabasca Basin, aiming to extend previously identified high-grade uranium mineralisation.

Broken Hill Mines has completed underground access to the high-grade Main Lode ore body at its Rasp Mine, delivering exceptional drilling results and targeting first ore extraction by November 2025.

S2 Resources has significantly expanded its Jillewarra project area over a highly prospective gold shear zone and completed drilling at West Murchison, with assay results pending. Meanwhile, Glenlogan assays returned no significant mineralisation.

Synlait Milk Limited reports a modest profit turnaround in FY25 and announces a major sale of its North Island assets to Abbott, aiming to reduce debt and sharpen its focus on core operations.

Synlait has agreed to sell its North Island assets to global healthcare giant Abbott for approximately US$178 million, marking a strategic reset focused on debt reduction and operational simplification. The deal, expected to close by April 2026, positions Synlait to concentrate on its South Island operations and explore new growth avenues.

Synlait Milk Limited reported an 11.7% rise in revenue to NZD 1.83 billion for the year ending July 2025, yet its net loss deepened sharply to nearly NZD 40 million, prompting a halt on dividends.